Facing frailty: Are you ready?

assessment tools clinical outcome frailty population aging rehabilitation

Journal

Bioscience trends
ISSN: 1881-7823
Titre abrégé: Biosci Trends
Pays: Japan
ID NLM: 101502754

Informations de publication

Date de publication:
15 Sep 2023
Historique:
medline: 20 9 2023
pubmed: 24 8 2023
entrez: 23 8 2023
Statut: ppublish

Résumé

By far, there is no general consensus concerning the definition of frailty even though it may be a global public health concern with aging of the population. It is regarded as a pathophysiological state before development of a severe illness that is associated with many adverse outcomes. Although previous studies attempted to verify its clinical value to prevent the development of serious illness, robust evidence is lacking. Based on previous studies of frailty, the current study analyzed the problems with existing investigations of frailty and it puts forward future strategies to improve those investigations. Finalizing the definition of frailty is the first step. Next, development of objective tools to identify/measure frailty based on the newest biological and computerized technologies is indispensable. Finally, well-designed clinical trials also need to be conducted to yield compelling evidence regarding the clinical value of medical interventions in frailty.

Identifiants

pubmed: 37612124
doi: 10.5582/bst.2023.01191
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-251

Auteurs

Tetsuya Asakawa (T)

Institute of Neurology, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.

Takashi Karako (T)

National Center for Global Health and Medicine, Tokyo, Japan.
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH